Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558510 | 0.78 | CYP1A2 (0.33) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL23558242 | 0.73 | CYP1A2 (0.34) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL23558511 | 0.73 | TYR (0.37) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL23558514 | 0.72 | CYP3A4 (0.40) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL23558298 | 0.71 | POLB (0.36) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL23558517 | 0.71 | CYP1A2 (0.34) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL25856859 | 0.65 | — | — | |
| SCHEMBL27843804 | 0.63 | CYP2A6 (0.44) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL21974591 | 0.63 | S1PR5 (0.38) | S1PR1RORCCYP2C9 | |
| SCHEMBL25856764 | 0.62 | PGR (0.41) | S1PR1CYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885RORC 888/4885CYP1A2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.